Financials

v3.20.1
CONDENSED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 8,038 $ 5,223
Receivables 1,551 993
Inventory 1,064 998
Prepaid expenses and other current assets 1,493 1,094
Total current assets 12,146 8,308
Property and equipment, net 780 817
Operating lease right-of-use asset 336 397
Total assets 13,262 9,522
Current liabilities:    
Accounts payable 1,332 1,401
Accrued clinical trials expenses 440 309
Accrued sales allowances 201 809
Other accrued liabilities 1,488 809
Operating lease liability, current 282 272
Current portion of long-term debt 667 0
Total current liabilities 4,410 3,600
Operating lease liability, non-current 76 150
Long-term debt 3,500 4,019
Warrant liability 0 320
Total liabilities 7,986 8,089
Stockholders' equity:    
Common stock, at amounts paid-in 93 57
Additional paid-in capital 359,804 350,413
Accumulated deficit (354,621) (349,037)
Total stockholders' equity 5,276 1,433
Total liabilities and stockholders' equity $ 13,262 $ 9,522

Source

v3.20.1
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Revenues:    
Total revenues $ 1,336 $ 945
Operating expenses:    
Cost of goods sold 171 304
Research and development 2,277 1,844
Selling, general and administrative 3,114 3,082
Total operating expenses 5,562 5,230
Loss from operations (4,226) (4,285)
Other expense:    
Interest expense, net (222) (246)
Non-cash loss on changes in the fair value of warrants (923) 0
Other income (expense), net (213) 14
Other expense, net (1,358) (232)
Net loss and comprehensive loss $ (5,584) $ (4,517)
Basic and diluted net loss per common share $ (0.07) $ (0.34)
Weighted average shares used in computing basic and diluted net loss per common share 82,641 13,217
License revenue    
Revenues:    
Total revenues $ 0 $ 313
Product revenue    
Revenues:    
Total revenues 210 317
Grant revenue    
Revenues:    
Total revenues $ 1,126 $ 315

Source

v3.20.1
CONDENSED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Cash flows from operating activities:    
Net loss $ (5,584) $ (4,517)
Adjustments to reconcile loss to net cash used in operating activities:    
Depreciation and amortization 62 60
Non-cash interest expense 148 169
Non-cash loss on changes in fair value of warrants 923 0
Stock-based compensation (84) 136
Finance costs attributable to issuance of warrants 211 0
Changes in operating assets and liabilities:    
Receivables (558) (315)
Inventory (66) 16
Contract assets 0 99
Prepaid expenses and other assets (399) (335)
Accounts payable (64) (326)
Accrued sales allowances (608) 887
Other accrued liabilities 810 145
Deferred revenue 0 (313)
Other (3) (14)
Net cash used in operating activities (5,212) (4,308)
Cash flows from investing activities:    
Purchases of property and equipment (30) (44)
Net cash used in investing activities (30) (44)
Cash flows from financing activities:    
Net proceeds from equity offerings 1,895 0
Net proceeds from the exercises of common stock warrants 6,162 605
Net cash provided by financing activities 8,057 605
Net decrease in cash and cash equivalents 2,815 (3,747)
Cash and cash equivalents at beginning of period 5,223 9,656
Cash and cash equivalents at end of period 8,038 5,909
Supplemental disclosure of cash flow information:    
Interest paid 102 109
Purchases of property and equipment included in accounts payable $ 6 $ 3

Source